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Abstract 22 
 23 
Stimulation of erythropoiesis by the third-generation erythropoietin drug CERA, a 24 
pegylated derivative of epoetin β, has provided valuable therapeutic benefits to patients 25 
suffering from renal anemia, but has also rapidly found application as an illicit 26 
performance-enhancing strategy in endurance sports. We present here a novel method for 27 
selective determination of CERA in serum, based on polyethylene glycol precipitation 28 
followed by a commercial homogeneous immunoassay. The developed method was 29 
highly discriminating between serum samples from CERA-treated patients and control 30 
subjects, as the covalently linked polyethylene glycol chain in CERA strongly enhanced 31 
the solubility of the protein in a polyethylene glycol–containing medium. Intravenous 32 
administration of CERA could be detected for several weeks in the majority of subjects 33 
tested. This assay outperforms the currently available CERA detection methods in terms 34 
of simplicity, convenience, cost, and throughput, making it ideal as a screening tool for 35 
doping control. 36 
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The recent introduction of long-acting pegylated erythropoietin (Epo) is an important 41 
improvement for the treatment of anemia in end-stage renal disease (9). Continuous Epo 42 
receptor activator (CERA) is synthesized by linking a methoxy-polyethylene glycol 43 
polymer to epoetin β, resulting in an extended plasma half-life and prolonged stimulation 44 
of erythropoiesis. In CERA, polyethylene glycol (PEG) accounts for ~50% of the 45 
molecular mass of the compound (60 kDa). 46 
Illicit use of recombinant Epo and Epo analogues, designated hereafter as 47 
erythropoiesis-stimulating agents (ESAs), for blood doping in endurance sports is 48 
currently detected by a method that combines isoelectric focusing (IEF) separation with 49 
double-blotting (1). This assay is technically capable of detecting CERA in both blood 50 
and urine specimens, but the poor urinary excretion of pegylated Epo may hamper the 51 
identification of CERA abuse when only a urine sample is analyzed (6). Blood testing has 52 
therefore been recommended as the method of choice (6). At present, the vast majority of 53 
samples collected for doping control purposes are urine specimens, but there is a growing 54 
awareness that blood may be the best matrix for detecting CERA and other forms of 55 
ESA-doping (12). The standard IEF-based detection method has proven its value, but is 56 
complicated and labor-intensive, and there is also a clear need for a novel and robust 57 
CERA assay in blood given the requirement for anti-doping laboratories to report an 58 
adverse analytical finding only when demonstrated by two different assay principles (15). 59 
PEG precipitation is widely used in analytical protein chemistry as a fractional 60 
precipitating agent and has proven valuable for the detection of serum macro-analytes, 61 
e.g. macroprolactine (14) and macro-enzymes (2, 7). We hypothesized that differences in 62 
physicochemical characteristics between CERA and endogenous Epo or non-pegylated 63 
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ESAs may lead to a different solubility in a PEG-containing medium, and set out to 64 
develop a test for specific determination of CERA in serum based on PEG precipitation 65 
followed by a homogeneous chemiluminescent immunoassay. 66 
 67 
Methods 68 
 69 
Subjects and serum samples 70 
A total of 96 patients (41 men and 55 women, aged 16–89 years) at Ghent University 71 
Hospital, Belgium, were included in this study. These patients belonged to one of the 72 
three following groups: (1) hemodialysis patients treated intravenously with CERA 73 
(Mircera®, Roche, Welwyn Garden City, United Kingdom) once every four weeks (dose 74 
range 50–350 µg) (n = 40), (2) non-renal patients not treated with CERA or other ESAs 75 
(n = 49), and (3) hemodialysis patients not treated with CERA or other ESAs (n = 7). 76 
Sex, age, and medication details for all individual patients are presented in Supplemental 77 
Tables 1–5. For 25 CERA-treated hemodialysis patients, serum samples were collected at 78 
week 1 (day 6, 7 or 8) following CERA administration. The other 15 CERA-treated 79 
hemodialysis patients were analyzed either at week 1 (day 6, 7 or 8), week 2 (day 14 or 80 
15), and week 4 (day 27 or 28) after CERA administration (n = 8), or at week 1 (day 7 or 81 
8), week 3 (day 13, 14 or 15), and week 4 (day 27 or 28) following CERA injection (n = 82 
7). A single serum sample was collected for all other patients. The study was approved by 83 
the local ethics committee, and written informed consent was obtained according to 84 
institutional protocols 2009/250 and 2009/253. 85 
 86 
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CERA and epoetin β standard solutions 87 
CERA (Mircera®) and epoetin β (Neorecormon®) were kindly provided by Roche. 88 
Standard curves were prepared by spiking a serum pool, obtained from persons with a 89 
normal hematocrit and not receiving ESAs, with 1000 IU/L CERA or 1000 IU/L epoetin 90 
β followed by serially diluting, in twofold increments, the spiked serum with unspiked 91 
serum from the same pool. Three separate standard curves were prepared for each ESA. 92 
 93 
Experimental protocol of the CERA assay 94 
For each patient sample or standard point, 150 µL serum was supplemented with 150 95 
µL of either a 50% (w/v) PEG-6000 solution or the solvent for PEG-6000 (saline 0.15 96 
mol/L) in separate microcentrifuge tubes. Following vortexing, incubation (37 °C, 15 97 
min), revortexing, centrifugation (9300 g, 10 min), and dilution of the supernatant (1:4 in 98 
saline 0.15 mol/L), Epo concentration was measured using the Access EPO assay 99 
(Beckman Coulter, Brea, CA) on an Access analyzer (Beckman Coulter). The Access 100 
EPO assay is a paramagnetic-particle chemoluminescent immunoassay developed for the 101 
quantitative determination of Epo levels in human serum and plasma (measurement 102 
range: 0.6–750 IU/L). Results are depicted as the PEG/control ratio, i.e. the ratio between 103 
the Epo concentration in the PEG-6000–pretreated aliquot and in the saline-pretreated 104 
aliquot. 105 
 106 
Statistical analysis 107 
All data were analyzed using GraphPad Prism version 5.01 for Windows (GraphPad 108 
Software, San Diego, CA). One-way ANOVA followed by Tukey’s multiple comparison 109 
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test was performed to analyze the serum samples for differences in PEG/control ratios 110 
among groups (hemodialysis patients treated with CERA, non-renal patients not treated 111 
with ESAs, hemodialysis patients not treated with ESAs). Statistical differences in 112 
PEG/control ratios between CERA and epoetin β standard solutions were assessed by 113 
two-sided two-sample t-tests. The level of statistical significance was set at P < 0.05 for 114 
all analyses. 115 
 116 
Results and Discussion 117 
 118 
Pegylation of a protein increases its water solubility as a result of the binding of two to 119 
three water molecules per ethylene oxide unit of PEG (10), and we therefore reasoned 120 
that the presence of a PEG chain in CERA may provide an opportunity for selective 121 
detection based on fractional precipitation. PEG itself was chosen as a suitable 122 
precipitant, since PEG solutions cause virtually no denaturation of proteins (13) and thus 123 
can be expected to preserve the native conformation of relevant epitopes. We decided to 124 
combine PEG precipitation with a commercially available, homogeneous immunoassay, 125 
with the aim to develop a convenient and simple method for selective determination of 126 
CERA in serum samples. 127 
In a first experiment, we analyzed serum samples that were collected from 128 
hemodialysis patients one week (at day 6, 7 or 8) following intravenous administration of 129 
CERA (dose range 50–350 µg), serum samples taken from non-renal patients not 130 
receiving CERA or other ESAs, and sera from hemodialysis patients not treated with 131 
CERA or other ESAs. Fig. 1 shows the overall results for each group of patients, while 132 
  
7
the clinical characteristics and individual results of all patients are presented in 133 
Supplemental Tables 1–3. In CERA-treated hemodialysis patients (n = 25), PEG 134 
pretreatment at a final concentration of 25% (w/v) PEG-6000 resulted in a 2.15-fold 135 
(95% confidence interval of the mean [95% CI]: 2.09–2.22) change in serum Epo levels 136 
relative to control pretreatment with saline. This increase in Epo concentration after PEG 137 
pretreatment presumably corresponded to a co-volume effect (voluminous pellet after 138 
PEG precipitation; no visible pellet after saline pretreatment). In contrast, the same 139 
procedure of PEG precipitation on serum samples from non-renal patients not treated 140 
with ESAs (n = 49) yielded a PEG/control ratio, determined as the ratio between the Epo 141 
level in the PEG-6000–pretreated aliquot and in the saline-pretreated aliquot, that was, on 142 
average, 0.92 (95% CI: 0.87–0.97). Similarly, serum samples from hemodialysis patients 143 
not treated with ESAs (n = 7) were characterized by a mean PEG/control ratio of 0.82 144 
(95% CI: 0.63–1.01). These results demonstrated that PEG precipitation of serum 145 
samples followed by immunoassay-based measurement of Epo concentration was highly 146 
effective in discriminating CERA-treated patients from control patients not treated with 147 
ESAs (CERA-treated hemodialysis patients versus non-renal patients not receiving 148 
ESAs: P < 0.001; CERA-treated hemodialysis patients versus hemodialysis patients not 149 
receiving ESAs: P < 0.001). 150 
We next evaluated whether the different solubility of CERA in 25% (w/v) PEG-6000 151 
was due to the presence of the covalently linked PEG chain, by directly comparing 152 
CERA with its non-pegylated counterpart, epoetin β. To this purpose, a serum pool, 153 
derived from individuals with a normal hematocrit and not treated with ESAs, was spiked 154 
with either 1000 IU/L CERA or 1000 IU/L epoetin β. The endogenous Epo level of the 155 
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serum pool was 9.12 IU/L. The spiked serum was subsequently serially diluted, in 156 
twofold increments, with unspiked serum from the same pool, down to a concentration of 157 
1.95 IU/L of the ESA (corresponding to a total Epo concentration of 11.07 IU/L). As 158 
shown in Fig. 2, our assay was capable of discriminating between the standard curve of 159 
CERA and the dilution series of epoetin β over the whole concentration range tested (P < 160 
0.01 for each concentration point). A higher PEG/control ratio was consistently observed 161 
for the CERA standard solutions compared to the corresponding epoetin β solutions, 162 
indicating that the PEG chain in CERA effectively increases the solubility of the 163 
molecule. 164 
Finally, we performed a time-course experiment aimed at exploration of the detection 165 
window of the assay after intravenous administration of CERA. Fifteen hemodialysis 166 
patients, different from those presented in Fig. 1, were selected for this experiment. It was 167 
decided, for the patient’s comfort, to investigate only leftovers from serum samples that 168 
were taken for routine diagnostic purposes, and this resulted in one group of patients that 169 
could be analyzed at week 1 (day 6, 7 or 8), week 2 (day 14 or 15), and week 4 (day 27 or 170 
28) following intravenous injection of CERA (n = 8, dose range 50–150 µg), and in 171 
another group of patients that could be evaluated at week 1 (day 7 or 8), week 3 (day 13, 172 
14 or 15), and week 4 (day 27 or 28) after intravenous CERA administration (n = 7, dose 173 
range 50–300 µg). Fig. 3A shows the distribution of the PEG/control ratios that were 174 
obtained at each time point for the 8 patients analyzed at weeks 1, 2, and 4 after CERA 175 
injection. Clinical characteristics and individual results of each patient are presented in 176 
Supplemental Table 4. The minimum PEG/control ratio observed was 1.86 at week 1 177 
(mean PEG/control ratio: 1.95; 95% CI: 1.89–2.01), 1.57 at week 2 (mean PEG/control 178 
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ratio: 1.76; 95% CI: 1.64–1.88), and 1.47 at week 4 (mean PEG/control ratio: 1.77; 95% 179 
CI: 1.54–2.00). All these values were higher than the maximum PEG/control ratio of the 180 
56 control patients analyzed in Fig. 1, which was equal to 1.30. For the 7 patients 181 
evaluated at weeks 1, 3, and 4 after CERA injection, PEG/control ratios lower than 1.30 182 
were not observed at week 1 (mean PEG/control ratio: 1.89; 95% CI: 1.75–2.03), but 183 
were recorded for 1 patient at week 3 (mean PEG/control ratio: 1.95; 95% CI: 1.50–2.39) 184 
and for 3 patients at week 4 (mean PEG/control ratio: 1.55; 95% CI: 1.04–2.05) (Fig. 3B 185 
and Supplemental Table 5). Taken together, these data demonstrated that a simple PEG 186 
precipitation followed by immunoassay-based Epo measurement was highly efficient in 187 
detecting the presence of CERA in the first two weeks after intravenous CERA 188 
administration and capable of detecting the majority, but not all, of the CERA-treated 189 
subjects at weeks 3 and 4 after injection (dose range 50–300 µg). 190 
We present here a rapid and simple method for selective determination of CERA in 191 
serum samples. A possible limitation of the study is that only CERA-treated hemodialysis 192 
patients have been included, which is due to ethical and practical considerations that 193 
hamper the recruitment of healthy sportsmen for a study with a prohibited doping 194 
substance. Another caveat is that we have not analyzed the serum samples in parallel by 195 
the conventional IEF-based detection method (1, 6), partly because this test has a number 196 
of pitfalls and is not always easy to interpret (3, 4, 8), and partly because the controlled 197 
medical setting of this study did not leave any uncertainty on whether CERA had been 198 
administered or not. From a practical point of view, the developed assay seems to offer 199 
several advantages for CERA doping detection compared to the standard ESA detection 200 
procedure. While the latter method is based on a complex and laborious workflow 201 
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consisting of immunoaffinity chromatography, ultrafiltration, IEF, and double-blotting, 202 
the assay proposed here is extremely simple, straightforward, more economical, and 203 
allows a high throughput, making it ideal as a screening tool. It should be noted that other 204 
alternative tests for CERA detection have recently been developed. Lamon et al. 205 
examined an enzyme-linked immunosorbent assay (ELISA) that relies on the 206 
combination of an anti-Epo and an anti-PEG antibody to specifically detect CERA 207 
doping in blood (5). Reichel et al. developed a sodium dodecyl sulfate–polyacrylamide 208 
gel electrophoresis (SDS-PAGE) method that allows the detection of endogenous Epo 209 
and various ESAs, including CERA, in urine, serum, and plasma samples (12). A 210 
drawback of the latter assay is that the sensitivity for CERA detection is relatively low, 211 
because binding of SDS to the PEG chain impairs the recognition of CERA by an anti-212 
Epo antibody. This problem has recently been solved by exchanging the SDS for sodium 213 
N-lauroyl sarosinate (SARCOSYL), which does not interact with PEG (11). The ELISA 214 
and SARCOSYL-PAGE methods for CERA detection have been reported to be sensitive, 215 
specific, and easier to perform than the sophisticated IEF-based assay, but they remain 216 
more cumbersome and time-consuming than the approach presented here. The 217 
availability of various methods with complementary detection principles offers 218 
opportunities for improving doping control. When serum samples have been collected 219 
from athletes, PEG precipitation combined with immunoassay-based Epo measurement 220 
may hold promise as a first-line assay to screen for the presence of CERA in view of its 221 
simplicity and speed, followed by one or more confirmatory methods. In addition, it can 222 
be anticipated that future drug development efforts will increasingly focus on Epo 223 
modifications that allow for enhanced stability, which may, in principle, be detectable by 224 
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this assay. In conclusion, the developed method presents a conceptually new approach for 225 
selective detection of pegylated Epo in serum and may prove a valuable adjunct in the 226 
fight against doping in sport. 227 
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Figure legends 280 
 281 
Fig. 1. PEG/control ratios for serum samples from CERA-treated patients and control 282 
patients. Serum samples were obtained from hemodialysis patients one week after 283 
intravenous administration of CERA (n = 25), from non-renal patients not treated with 284 
ESAs (n = 49), and from hemodialysis patients not treated with ESAs (n = 7). 285 
PEG/control ratios were determined as described in Methods. The horizontal line, box, 286 
and whiskers of each boxplot represent the median, the interquartile range, and the upper 287 
and lower range of the data, respectively. HD, hemodialysis. 288 
 289 
Fig. 2. PEG/control ratios for CERA- and epoetin β–spiked serum. For each ESA, three 290 
separate dilution series were prepared and PEG/control ratios were determined, as 291 
described in Methods. Points represent the mean PEG/control ratios of the three 292 
experiments, and error bars indicate standard deviations. 293 
 294 
Fig. 3. PEG/control ratios for serum samples at different time points following 295 
intravenous administration of CERA. Serum samples were collected from hemodialysis 296 
patients at 1, 2, and 4 weeks after intravenous CERA administration (A; n = 8, dose range 297 
50–150 µg) and at 1, 3, and 4 weeks following intravenous CERA injection (B; n = 7, 298 
dose range 50–300 µg). PEG/control ratios were determined as described in Methods. 299 
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